EQT Life Sciences-Backed AgomAb Falls 8% After $200 Million IPO
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company backed by EQT Life Sciences, opened 8.1% below its IPO price on Friday after the firm raised $200 million in a listing.
By Angel Adegbesan · Bloomberg
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company backed by EQT Life Sciences, opened 8.1% below its IPO price on Friday after the firm raised $200 million in a listing.